Polymorphisms in methotrexate pathways: What is clinically relevant, what is not, and what is promising

Current Drug Metabolism

Volumn 10, Issue 6, 2009, Pages 547-566

  Gervasini, Guillermo ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

Acute lymphoblastic leuk mia; Efficiency; Folate; Methotrexate; Polymorphism; Rheumatoid arthritis; Toxicity

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ADENOSINE; ADENOSINE MONOPHOSPHATE DEAMINASE; ADENOSINE RECEPTOR; ALANINE; CORTICOSTEROID; CYCLOSPORIN A; CYSTEINE; DIHYDROFOLATE REDUCTASE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FLUOROURACIL; FOLIC ACID; FOLYLPOLYGLUTAMATE SYNTHASE; GAMMA GLUTAMYL HYDROLASE; GLYCINE; GLYCINE HYDROXYMETHYLTRANSFERASE; HOMOCYSTEINE; INOSINE TRIPHOSPHATE; INOSINE TRIPHOSPHATE PYROPHOSPHATASE; MEPREDNISONE; METHIONINE SYNTHASE; METHIONINE SYNTHASE REDUCTASE; METHOTREXATE; METHYLENETETRAHYDROFOLATE DEHYDROGENASE; PHOSPHORIBOSYLAMINOIMIDAZOLECARBOXAMIDE FORMYLTRANSFERASE; REDUCED FOLATE CARRIER; SALAZOSULFAPYRIDINE; THREONINE; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALOPECIA; AMINO ACID SUBSTITUTION; ATTENTION DEFICIT DISORDER; BLOOD TOXICITY; BREAST CANCER; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG TRANSPORT; ENZYME ACTIVITY; FOLATE METABOLISM; GASTROINTESTINAL SYMPTOM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GRAFT VERSUS HOST REACTION; HAPLOTYPE; HEADACHE; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; LUNG DISEASE; LYMPHOMA; NEUROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PHARMACOGENETICS; PROTEIN METHYLATION; PSORIASIS; PYRIMIDINE SYNTHESIS; RASH; REVIEW; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 70450241056     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920009789375414     Document Type: Review

References (142)

1. Kremer, J.M. Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann. Intern. Med., 2001, 134(8), 695-706.
2. Strand, V.; Cohen, S.; Schiff, M.; Weaver, A.; Fleischmann, R.; Cannon, G.; Fox, R.; Moreland, L.; Olsen, N.; Furst, D.; Caldwell, J.; Kaine, J.; Sharp, J.; Hurley, F.; Loew-Friedrich, I. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch. Intern. Med., 1999, 159(21), 2542-2550
3. Pui, C.H.; Evans, W.E. Treatment of acute lymphoblastic leukemia. N. Engl. J. Med., 2006, 354(2), 166-178
4. Schmeling, H.; Biber, D.; Heins, S.; Horneff, G. Influence of methylenetetrahydrofolate reductase polymorphisms on efficacy and toxicity of methotrexate in patients with juvenile idiopathic arthritis. J. Rheumatol., 2005, 32(9), 1832-1836 (Pubitemid 41324827)
5. Gemmati, D.; Ongaro, A.; Tognazzo, S.; Catozzi, L.; Federici, F.; Mauro, E.; Della Porta, M.; Campioni, D.; Bardi, A.; Gilli, G.; Pellati, A.; Caruso, A.; Scapoli, G.L.; De Mattei, M. Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival. Haematologica, 2007, 92(4), 478-485 (Pubitemid 350144293)
6. Robien, K.; Schubert, M.M.; Bruemmer, B.; Lloid, M.E.; Potter, J.D.; Ulrich, C.M. Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. J. Clin. Oncol., 2004, 22(7), 1268-1275
7. van Ede, A.E.; Laan, R.F.; Blom, H.J.; Huizinga, T.W.; Haagsma, C.J.; Giesendorf, B.A.; de Boo, T.M.; van de Putte, L.B. The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis. Rheum., 2001, 44(11), 2525-2530
8. Weisman, M.H.; Furst, D.E.; Park, G.S.; Kremer, J.M.; Smith, K.M.; Wallace, D.J.; Caldwell, J.R.; Dervieux, T. Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. Arthritis. Rheum., 2006, 54(2), 607-612 (Pubitemid 43228638)
9. Ulrich, C.M.; Yasui, Y.; Storb, R.; Schubert, M.M.; Wagner, J.L.; Bigler, J.; Ariail, K.S.; Keener, C.L.; Li, S.; Liu, H.; Farin, F.M.; Potter, J.D. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood, 2001, 98(1), 231-234
10. Kim, I.; Lee, K.H.; Kim, J.H.; Ra, E.K.; Yoon, S.S.; Hong, Y.C.; Park, S.S.; Kim, C.S.; Park, S.; Kim, B.K. Polymorphisms of the methylenetetrahydrofolate reductase gene and clinical outcomes in HLA-matched sibling allogeneic hematopoietic stem cell transplantation. Ann. Hematol., 2007, 86(1), 41-48 (Pubitemid 46138317)
11. Pietrzyk, J.J.; Bik-Multanowski, M.; Balwierz, W.; Skoczen, S.; Wojcik, D.; Chybicka, A.; Sikorska-Fic, B.; Matysiak, M.; Szczepanski, T.; Sonta-Jakimczyk, D.; Ploszynska, A.; Balcerska, A.; Mycko, K.; Bodalski, J.; Krawczuk-Rybak, M.; Kowalczyk, J.; Koltan, A.; Sobol, G.; Derwich, K.; Kwinta, P. Additional genetic risk factor for death in children with acute lymphoblastic leukemia: a common polymorphism of the MTHFR gene. Pediatr. Blood Cancer, 2009, 52(3), 364-368
12. Moscow, J.A.; Gong, M.; He, R.; Sgagias, M.K.; Dixon, K.H.; Anzick, S.L.; Meltzer, P.S.; Cowan, K.H. Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Res., 1995, 55(17), 3790-3794
13. Chabner, B.A.; Allegra, C.J.; Curt, G.A.; Clendeninn, N.J.; Baram, J.; Koizumi, S.; Drake, J.C.; Jolivet, J. Polyglutamation of methotrexate. Is methotrexate a prodrug? J. Clin. Invest., 1985, 76(3), 907-912
14. Szeto, D.W.; Cheng, Y.C.; Rosowsky, A.; Yu, C.S.; Modest, E.J.; Piper, J.R.; Temple, C., Jr.; Elliott, R.D.; Rose, J.D.; Montgomery, J.A. Human thymidylate synthetase - III. Effects of methotrexate and folate analogs. Biochem. Pharmacol., 1979, 28(17), 2633-2637
15. Galivan, J. Evidence for the cytotoxic activity of polyglutamate derivatives of methotrexate. Mol. Pharmacol., 1980, 17(1), 105-110 (Pubitemid 10176280)
16. Allegra, C.J.; Drake, J.C.; Jolivet, J.; Chabner, B.A. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc. Natl. Acad. Sci. USA, 1985, 82(15), 4881-4885
17. De Mattia, E.; Toffoli, G. C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation. Eur. J. Cancer, 2009, 45(8), 1333-1351
18. Frosst, P.; Blom, H.J.; Milos, R.; Goyette, P.; Sheppard, C.A.; Matthews, R.G.; Boers, G.J.; den Heijer, M.; Kluijtmans, L.A.; van den Heuvel, L.P.; Rozen, R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet., 1995, 10(1), 111-113
19. Brattstrom, L.; Zhang, Y.; Hurtig, M.; Refsum, H.; Ostensson, S.; Fransson, L.; Jones, K.; Landgren, F.; Brudin, L.; Ueland, P.M. A common methylenetetrahydrofolate reductase gene mutation and longevity. Atherosclerosis, 1998, 141(2), 315-319 (Pubitemid 28539639)
20. Chiusolo, P.; Reddiconto, G.; Casorelli, I.; Laurenti, L.; Sora, F.; Mele, L.; Annino, L.; Leone, G.; Sica, S. Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann. Oncol., 2002, 13(12), 1915-1918 (Pubitemid 36040780)
21. Chiusolo, P.; Reddiconto, G.; Farina, G.; Mannocci, A.; Fiorini, A.; Palladino, M.; La Torre, G.; Fianchi, L.; Sora, F.; Laurenti, L.; Leone, G.; Sica, S. MTHFR polymorphisms' influence on outcome and toxicity in acute lymphoblastic leukemia patients. Leuk. Res., 2007, 31(12), 1669-1674 (Pubitemid 350051399)
22. Shimasaki, N.; Mori, T.; Torii, C.; Sato, R.; Shimada, H.; Tanigawara, Y.; Kosaki, K.; Takahashi, T. Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma. J. Pediatr. Hematol. Oncol., 2008, 30(5), 347-352 (Pubitemid 351643456)
23. Toffoli, G.; Russo, A.; Innocenti, F.; Corona, G.; Tumolo, S.; Sartor, F.; Mini, E.; Boiocchi, M. Effect of methylenetetrahydrofolate reductase 677C - >T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int. J. Cancer, 2003, 103(3), 294-299 (Pubitemid 36076421)
24. Toffoli, G.; Veronesi, A.; Boiocchi, M.; Crivellari, D. MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF). Ann. Oncol., 2000, 11(3), 373-374 (Pubitemid 30214680)
25. Urano, W.; Taniguchi, A.; Yamanaka, H.; Tanaka, E.; Nakajima, H.; Matsuda, Y.; Akama, H.; Kitamura, Y.; Kamatani, N. Polymorphisms in the methylenetetrahydrofolate reductase gene were asso ciated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics, 2002, 12(3), 183-190 (Pubitemid 34596782)
26. Ranganathan, P.; Culverhouse, R.; Marsh, S.; Mody, A.; Scott- Horton, T.J.; Brasington, R.; Joseph, A.; Reddy, V.; Eisen, S.; McLeod, H.L. Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J. Rheumatol., 2008, 35(4), 572-579
27. Taniguchi, A.; Urano, W.; Tanaka, E.; Furihata, S.; Kamitsuji, S.; Inoue, E.; Yamanaka, M.; Yamanaka, H.; Kamatani, N. Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice. Pharmacogenet. Genomics, 2007, 17(6), 383-390 (Pubitemid 46763383)
28. Robien, K.; Ulrich, C.M.; Bigler, J.; Yasui, Y.; Gooley, T.; Bruemmer, B.; Potter, J.D.; Radich, J.P. Methylenetetrahydrofolate reductase genotype affects risk of relapse after hematopoietic cell transplantation for chronic myelogenous leukemia. Clin. Cancer Res., 2004, 10(22), 7592-7598
29. Seidemann, K.; Book, M.; Zimmermann, M.; Meyer, U.; Welte, K.; Stanulla, M.; Reiter, A. MTHFR 677 (C - >T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95. Ann. Hematol., 2006, 85(5), 291-300. (Pubitemid 43732651)
30. Huang, L.; Tissing, W.J.; de Jonge, R.; van Zelst, B.D.; Pieters, R. Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia. Leukemia, 2008, 22(9), 1798-1800
31. Kishi, S.; Griener, J.; Cheng, C.; Das, S.; Cook, E.H.; Pei, D.; Hudson, M.; Rubnitz, J.; Sandlund, J.T.; Pui, C.H.; Relling, M.V. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J. Clin. Oncol., 2003, 21(16), 3084-3091
32. Ruiz-Arguelles, G.J.; Coconi-Linares, L.N.; Garces-Eisele, J.; Reyes-Nunez, V. Methotrexate-induced mucositis in acute leukemia patients is not associated with the MTHFR 677T allele in Mexico. Hematology, 2007, 12(5), 387-391 (Pubitemid 47487846)
33. Aplenc, R.; Lange, B. Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia. Br. J. Haematol., 2004, 125(4), 421-434 (Pubitemid 38916188)
34. Shimasaki, N.; Mori, T.; Samejima, H.; Sato, R.; Shimada, H.; Yahagi, N.; Torii, C.; Yoshihara, H.; Tanigawara, Y.; Takahashi, T.; Kosaki, K. Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J. Pediatr. Hematol. Oncol., 2006, 28(2), 64-68 (Pubitemid 43315660)
35. Aggarwal, P.; Naik, S.; Mishra, K.P.; Aggarwal, A.; Misra, R. Correlation between methotrexate efficacy & toxicity with C677T polymorphism of the methylenetetrahydrofolate gene in rheumatoid arthritis patients on folate supplementation. Indian J. Med. Res., 2006, 124(5), 521-526 (Pubitemid 46157711)
36. Hughes, L.B.; Beasley, T.M.; Patel, H.; Tiwari, H.K.; Morgan, S.L.; Baggott, J.E.; Saag, K.G.; McNicholl, J.; Moreland, L.W.; Alarcon, G.S.; Bridges, S.L., Jr. Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Ann. Rheum. Dis., 2006, 65(9), 1213-1218
37. Kumagai, K.; Hiyama, K.; Oyama, T.; Maeda, H.; Kohno, N. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int. J. Mol. Med., 2003, 11(5), 593-600.
38. Berkun, Y.; Levartovsky, D.; Rubinow, A.; Orbach, H.; Aamar, S.; Grenader, T.; Abou Atta, I.; Mevorach, D.; Friedman, G.; Ben- Yehuda, A. Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann. Rheum. Dis., 2004, 63(10), 1227-1231
39. Ghodke, Y.; Chopra, A.; Joshi, K.; Patwardhan, B. Are Thymidylate synthase and Methylene tetrahydrofolate reductase genes linked with methotrexate response (efficacy, toxicity) in Indian (Asian) rheumatoid arthritis patients? Clin. Rheumatol., 2008, 27(6), 787-789
40. Campalani, E.; Arenas, M.; Marinaki, A.M.; Lewis, C.M.; Barker, J.N.; Smith, C.H. Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. J. Invest. Dermatol., 2007, 127(8), 1860-1867
41. Warren, R.B.; Smith, R.L.; Campalani, E.; Eyre, S.; Smith, C.H.; Barker, J.N.; Worthington, J.; Griffiths, C.E. Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. Br. J. Dermatol., 2009, 160(2), 438-441
42. Fisher, M.C.; Cronstein, B.N. Metaanalysis of Methylenetetrahydrofolate Reductase (MTHFR) Polymorphisms affecting methotrexate toxicity. J. Rheumatol., 2009, 36(3), 539-545
43. Krajinovic, M.; Lemieux-Blanchard, E.; Chiasson, S.; Primeau, M.; Costea, I.; Moghrabi, A. Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J., 2004, 4(1), 66-72. (Pubitemid 38256607)
44. Aplenc, R.; Thompson, J.; Han, P.; La, M.; Zhao, H.; Lange, B.; Rebbeck, T. Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res., 2005, 65(6), 2482-2487 (Pubitemid 40490161)
45. Sugimoto, K.; Murata, M.; Onizuka, M.; Inamoto, Y.; Terakura, S.; Kuwatsuka, Y.; Oba, T.; Miyamura, K.; Kodera, Y.; Naoe, T. Decreased risk of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with the 5,10- methylenetetrahydrofolate reductase 677TT genotype. Int. J. Hematol., 2008, 87(5), 451-458
46. Robien, K.; Bigler, J.; Yasui, Y.; Potter, J.D.; Martin, P.; Storb, R.; Ulrich, C.M. Methylenetetrahydrofolate reductase and thymidylate synthase genotypes and risk of acute graft-versus-host disease following hematopoietic cell transplantation for chronic myelogenous leukemia. Biol. Blood Marrow Transplant., 2006, 12(9), 973-980
47. Dervieux, T.; Greenstein, N.; Kremer, J. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum., 2006, 54(10), 3095-3103 (Pubitemid 44622078)
48. Wessels, J.A.; de Vries-Bouwstra, J.K.; Heijmans, B.T.; Slagboom, P.E.; Goekoop-Ruiterman, Y.P.; Allaart, C.F.; Kerstens, P.J.; van Zeben, D.; Breedveld, F.C.; Dijkmans, B.A.; Huizinga, T.W.; Guchelaar, H.J. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum., 2006, 54(4), 1087-1095
49. Kurzawski, M.; Pawlik, A.; Safranow, K.; Herczynska, M.; Drozdzik, M. 677C>T and 1298A>C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics, 2007, 8(11), 1551-1559 (Pubitemid 350286399)
50. van der Put, N.M.; Gabreels, F.; Stevens, E.M.; Smeitink, J.A.; Trijbels, F.J.; Eskes, T.K.; van den Heuvel, L.P.; Blom, H.J. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am. J. Hum. Genet., 1998, 62(5), 1044-1051 (Pubitemid 28199004)
51. Weisberg, I.; Tran, P.; Christensen, B.; Sibani, S.; Rozen, R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol. Genet. Metab., 1998, 64(3), 169-172 (Pubitemid 28453294)
52. Shirley, M.A.; Wheelan, P.; Howell, S.R.; Murphy, R.C. Oxidative metabolism of a rexinoid and rapid phase II metabolite identification by mass spectrometry. Drug. Metab. Dispos., 1997, 25(10), 1144-1149
53. Lievers, K.J.; Boers, G.H.; Verhoef, P.; den Heijer, M.; Kluijtmans, L.A.; van der Put, N.M.; Trijbels, F.J.; Blom, H.J. A second common variant in the methylenetetrahydrofolate reductase (MTHFR) gene and its relationship to MTHFR enzyme activity, homocysteine, and cardiovascular disease risk. J. Mol. Med., 2001, 79(9), 522-528
54. Herrlinger, K.R.; Cummings, J.R.; Barnardo, M.C.; Schwab, M.; Ahmad, T.; Jewell, D.P. The pharmacogenetics of methotrexate in inflammatory bowel disease. Pharmacogenet. Genomics, 2005, 15(10), 705-711 (Pubitemid 41345322)
55. Goekkurt, E.; Stoehlmacher, J.; Stueber, C.; Wolschke, C.; Eiermann, T.; Iacobelli, S.; Zander, A.R.; Ehninger, G.; Kroger, N. Pharmacogenetic analysis of liver toxicity after busul fan/cyclophosphamide-based allogeneic hematopoietic stem cell transplantation. Anticancer Res., 2007, 27(6C), 4377-4380
56. Ulvik, A.; Ueland, P.M.; Fredriksen, A.; Meyer, K.; Vollset, S.E.; Hoff, G.; Schneede, J. Functional inference of the methylenetetrahydrofolate reductase 677C > T and 1298A > C polymorphisms from a large-scale epidemiological study. Hum. Genet., 2007, 121(1), 57-64. (Pubitemid 46421141)
57. Karas Kuzelicki, N.; Milek, M.; Jazbec, J.; Mlinaric-Rascan, I. 5,10-Methylenetetrahydrofolate reductase (MTHFR) low activity genotypes reduce the risk of relapse-related acute lymphoblastic leukemia (ALL). Leuk. Res., 2009, 33(10), 1344-1348
58. Krull, K.R.; Brouwers, P.; Jain, N.; Zhang, L.; Bomgaars, L.; Dreyer, Z.; Mahoney, D.; Bottomley, S.; Okcu, M.F. Folate pathway genetic polymorphisms are related to attention disorders in childhood leukemia survivors. J. Pediatr., 2008, 152(1), 101-105
59. Welsh, S.J.; Titley, J.; Brunton, L.; Valenti, M.; Monaghan, P.; Jackman, A.L.; Aherne, G.W. Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues. Clin. Cancer Res., 2000, 6(6), 2538-2546
60. Horie, N.; Aiba, H.; Oguro, K.; Hojo, H.; Takeishi, K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell. Struct. Funct., 1995, 20(3), 191-197
61. Krajinovic, M.; Costea, I.; Chiasson, S. Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet, 2002, 359(9311), 1033-1034 (Pubitemid 34286543)
62. Li, W.; Fan, J.; Hochhauser, D.; Banerjee, D.; Zielinski, Z.; Almasan, A.; Yin, Y.; Kelly, R.; Wahl, G.M.; Bertino, J.R. Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. Proc. Natl. Acad. Sci. USA, 1995, 92(22), 10436-10440
63. Costea, I.; Moghrabi, A.; Krajinovic, M. The influence of cyclin D1 (CCND1) 870A>G polymorphism and CCND1-thymidylate synthase (TS) gene-gene interaction on the outcome of childhood acute lymphoblastic leukaemia. Pharmacogenetics, 2003, 13(9), 577-580 (Pubitemid 37159635)
64. Dulucq, S.; St-Onge, G.; Gagne, V.; Ansari, M.; Sinnett, D.; Labuda, D.; Moghrabi, A.; Krajinovic, M. DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL. Blood, 2008, 111(7), 3692-3700
65. Dervieux, T.; Furst, D.; Lein, D.O.; Capps, R.; Smith, K.; Walsh, M.; Kremer, J. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum., 2004, 50(9), 2766-2774 (Pubitemid 39209513)
66. Takatori, R.; Takahashi, K.A.; Tokunaga, D.; Hojo, T.; Fujioka, M.; Asano, T.; Hirata, T.; Kawahito, Y.; Satomi, Y.; Nishino, H.; Tanaka, T.; Hirota, Y.; Kubo, T. ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. Clin. Exp. Rheumatol., 2006, 24(5), 546-554 (Pubitemid 44911249)
67. de Jonge, R.; Hooijberg, J.H.; van Zelst, B.D.; Jansen, G.; van Zantwijk, C.H.; Kaspers, G.J.; Peters, G.J.; Ravindranath, Y.; Pieters, R.; Lindemans, J. Effect of polymorphisms in folate-related genes on in. vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia. Blood, 2005, 106(2), 717-720 (Pubitemid 40981271)
68. Pare, L.; Altes, A.; Ramon y Cajal, T.; Del Rio, E.; Alonso, C.; Sedano, L.; Barnadas, A.; Baiget, M. Influence of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms on the disease-free survival of breast cancer patients receiving adjuvant 5-fluorouracil/ methotrexate-based therapy. Anticancer Drugs, 2007, 18(7), 821-825
69. Bohanec Grabar, P.; Logar, D.; Lestan, B.; Dolzan, V. Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism. Eur. J. Clin. Pharmacol., 2008, 64(11), 1057-1068
70. Ulrich, C.M.; Bigler, J.; Velicer, C.M.; Greene, E.A.; Farin, F.M.; Potter, J.D. Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol. Biomarkers. Prev., 2000, 9(12), 1381-1385
71. Mandola, M.V.; Stoehlmacher, J.; Zhang, W.; Groshen, S.; Yu, M.C.; Iqbal, S.; Lenz, H.J.; Ladner, R.D. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics, 2004, 14(5), 319-327
72. Patino-Garcia, A.; Zalacain, M.; Marrodan, L.; San-Julian, M.; Sierrasesumaga, L. Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression. J. Pediatr, 2009, 154(5), 688-693
73. Matherly, L.H.; Taub, J.W.; Ravindranath, Y.; Proefke, S.A.; Wong, S.C.; Gimotty, P.; Buck, S.; Wright, J.E.; Rosowsky, A. Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia. Blood, 1995, 85(2), 500-509
74. Sinnett, D.; Beaulieu, P.; Belanger, H.; Lefebvre, J.F.; Langlois, S.; Theberge, M.C.; Drouin, S.; Zotti, C.; Hudson, T.J.; Labuda, D. Detection and characterization of DNA variants in the promoter regions of hundreds of human disease candidate genes. Genomics, 2006, 87(6), 704-710
75. Goto, Y.; Yue, L.; Yokoi, A.; Nishimura, R.; Uehara, T.; Koizumi, S.; Saikawa, Y. A novel single-nucleotide polymorphism in the 3′- untranslated region of the human dihydrofolate reductase gene with enhanced expression. Clin. Cancer. Res., 2001, 7(7), 1952-1956 (Pubitemid 32994830)
76. Girgis, S.; Suh, J.R.; Jolivet, J.; Stover, P.J. 5-Formyltetrahydrofolate regulates homocysteine remethylation in human neuroblastoma. J. Biol. Chem., 1997, 272(8), 4729-4734
77. Heil, S.G.; Van der Put, N.M.; Waas, E.T.; den Heijer, M.; Trijbels, F.J.; Blom, H.J. Is mutated serine hydroxymethyltransferase (SHMT) involved in the etiology of neural tube defects? Mol. Genet. Metab., 2001, 73(2), 164-172
78. Skibola, C.F.; Smith, M.T.; Hubbard, A.; Shane, B.; Roberts, A.C.; Law, G.R.; Rollinson, S.; Roman, E.; Cartwright, R.A.; Morgan, G.J. Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. Blood, 2002, 99(10), 3786-3791
79. Wessels, J.A.; van der Kooij, S.M.; le Cessie, S.; Kievit, W.; Barerra, P.; Allaart, C.F.; Huizinga, T.W.; Guchelaar, H.J. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum., 2007, 56(6), 1765-1775
80. Shane, B. Folylpolyglutamate synthesis and role in the regulation of one-carbon metabolism. Vitam. Horm., 1989, 45, 263-335.
81. Hol, F.A.; van der Put, N.M.; Geurds, M.P.; Heil, S.G.; Trijbels, F.J.; Hamel, B.C.; Mariman, E.C.; Blom, H.J. Molecular genetic analysis of the gene encoding the trifunctional enzyme MTHFD (methylenetetrahydrofolate- dehydrogenase, methenyltetrahydrofolate- cyclohydrolase, formyltetrahydrofolate synthetase) in patients with neural tube defects. Clin. Genet., 1998, 53(2), 119-125
82. Brody, L.C.; Conley, M.; Cox, C.; Kirke, P.N.; McKeever, M.P.; Mills, J.L.; Molloy, A.M.; O'Leary, V.B.; Parle-McDermott, A.; Scott, J.M.; Swanson, D.A. A polymorphism, R653Q, in the trifunctional enzyme methylenetetrahydrofolate dehydrogenase/ methenyltetrahydrofolate cyclohydrolase/formyltetrahydrofolate synthetase is a maternal genetic risk factor for neural tube defects: report of the Birth Defects Research Group. Am. J. Hum. Genet., 2002, 71(5), 1207-1215
83. Christensen, K.E.; Rohlicek, C.V.; Andelfinger, G.U.; Michaud, J.; Bigras, J.L.; Richter, A.; Mackenzie, R.E.; Rozen, R. The MTHFD1 p.Arg653Gln variant alters enzyme function and increases risk for congenital heart defects. Hum. Mutat., 2009, 30(2), 212-220
84. Leclerc, D.; Campeau, E.; Goyette, P.; Adjalla, C.E.; Christensen, B.; Ross, M.; Eydoux, P.; Rosenblatt, D.S.; Rozen, R.; Gravel, R.A. Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. Hum. Mol. Genet., 1996, 5(12), 1867-1874
85. Harmon, D.L.; Shields, D.C.; Woodside, J.V.; McMaster, D.; Yarnell, J.W.; Young, I.S.; Peng, K.; Shane, B.; Evans, A.E.; Whitehead, A.S. Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations. Genet. Epidemiol., 1999, 17(4), 298-309.
86. Berkun, Y.; Abou Atta, I.; Rubinow, A.; Orbach, H.; Levartovsky, D.; Aamar, S.; Arbel, O.; Dresner-Pollak, R.; Friedman, G.; Ben- Yehuda, A. 2756GG genotype of methionine synthase reductase gene is more prevalent in rheumatoid arthritis patients treated with methotrexate and is associated with methotrexate-induced nodulosis. J. Rheumatol., 2007, 34(8), 1664-1669
87. Krajinovic, M.; Robaey, P.; Chiasson, S.; Lemieux-Blanchard, E.; Rouillard, M.; Primeau, M.; Bournissen, F.G.; Moghrabi, A. Polymorphisms of genes controlling homocysteine levels and IQ score following the treatment for childhood ALL. Pharmacogenomics, 2005, 6(3), 293-302. (Pubitemid 40601632)
88. Wessels, J.A.; Kooloos, W.M.; De Jonge, R.; De Vries-Bouwstra, J.K.; Allaart, C.F.; Linssen, A.; Collee, G.; De Sonnaville, P.; Lindemans, J.; Huizinga, T.W.; Guchelaar, H.J. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum., 2006, 54(9), 2830-2839
89. Wilson, A.; Platt, R.; Wu, Q.; Leclerc, D.; Christensen, B.; Yang, H.; Gravel, R.A.; Rozen, R. A common variant in methionine synthase reductase combined with low cobalamin (vitamin B12) increases risk for spina bifida. Mol. Genet. Metab., 1999, 67(4), 317-323 (Pubitemid 29406795)
90. Gaughan, D.J.; Kluijtmans, L.A.; Barbaux, S.; McMaster, D.; Young, I.S.; Yarnell, J.W.; Evans, A.; Whitehead, A.S. The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. Atherosclerosis, 2001, 157(2), 451-456
91. Jacques, P.F.; Bostom, A.G.; Selhub, J.; Rich, S.; Ellison, R.C.; Eckfeldt, J.H.; Gravel, R.A.; Rozen, R. Effects of polymorphisms of methionine synthase and methionine synthase reductase on total plasma homocysteine in the NHLBI Family Heart Study. Atherosclerosis, 2003, 166(1), 49-55. (Pubitemid 35449600)
92. Cronstein, B.N.; Eberle, M.A.; Gruber, H.E.; Levin, R.I. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc. Natl. Acad. Sci. USA, 1991, 88(6), 2441-2445
93. Dervieux, T.; Brenner, T.L.; Hon, Y.Y.; Zhou, Y.; Hancock, M.L.; Sandlund, J.T.; Rivera, G.K.; Ribeiro, R.C.; Boyett, J.M.; Pui, C.H.; Relling, M.V.; Evans, W.E. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. Blood, 2002, 100(4), 1240-1247
94. Sumi, S.; Marinaki, A.M.; Arenas, M.; Fairbanks, L.; Shobowale- Bakre, M.; Rees, D.C.; Thein, S.L.; Ansari, A.; Sanderson, J.; De Abreu, R.A.; Simmonds, H.A.; Duley, J.A. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum. Genet., 2002, 111(4-5), 360-367 (Pubitemid 36075062)
95. Lee, Y.C.; Cui, J.; Costenbader, K.H.; Shadick, N.A.; Weinblatt, M.E.; Karlson, E.W. Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate. Rheumatology (Oxford), 2009, 48(6), 613-617
96. Morisaki, T.; Gross, M.; Morisaki, H.; Pongratz, D.; Zollner, N.; Holmes, E.W. Molecular basis of AMP deaminase deficiency in skeletal muscle. Proc. Natl. Acad. Sci. USA, 1992, 89(14), 6457-6461
97. Riksen, N.P.; Rongen, G.A.; Smits, P.; van Riel, P.; Barrera, P. Effect of the 34C>T variant in the AMPD1 gene on the clinical response to methotrexate in patients with rheumatoid arthritis: comment on the article by Wessels et. al. Arthritis Rheum., 2007, 56(2), 694; author reply 694-695
98. van Ede, A.E.; Laan, R.F.; De Abreu, R.A.; Stegeman, A.B.; van de Putte, L.B. Purine enzymes in patients with rheumatoid arthritis treated with methotrexate. Ann. Rheum. Dis., 2002, 61(12), 1060-1064 (Pubitemid 35397351)
99. Hirschhorn, R.; Yang, D.R.; Israni, A. An Asp8Asn substitution results in the adenosine deaminase (ADA) genetic polymorphism (ADA 2 allozyme): occurrence on different chromosomal backgrounds and apparent intragenic crossover. Ann. Hum. Genet., 1994, 58(Pt 1), 1-9. (Pubitemid 24110508)
100. Cutolo, M.; Sulli, A.; Pizzorni, C.; Seriolo, B.; Straub, R.H. Antiinflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann. Rheum. Dis., 2001, 60(8), 729-735 (Pubitemid 32685871)
101. Warren, R.B.; Smith, R.L.; Campalani, E.; Eyre, S.; Smith, C.H.; Barker, J.N.; Worthington, J.; Griffiths, C.E. Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J. Invest. Dermatol., 2008, 128(8), 1925-1929
102. Hider, S.L.; Thomson, W.; Mack, L.F.; Armstrong, D.J.; Shadforth, M.; Bruce, I.N. Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX. Rheumatology (Oxford), 2008, 47(8), 1156-1159
103. Cheng, Q.; Wu, B.; Kager, L.; Panetta, J.C.; Zheng, J.; Pui, C.H.; Relling, M.V.; Evans, W.E. A substrate specific functional polymorphism of human gamma-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells. Pharmacogenetics, 2004, 14(8), 557-567
104. Chave, K.J.; Ryan, T.J.; Chmura, S.E.; Galivan, J. Identification of single nucleotide polymorphisms in the human gamma-glutamyl hydrolase gene and characterization of promoter polymorphisms. Gene, 2003, 319, 167-175 (Pubitemid 37346211)
105. Dervieux, T.; Kremer, J.; Lein, D.O.; Capps, R.; Barham, R.; Meyer, G.; Smith, K.; Caldwell, J.; Furst, D.E. Contribution of common polymorphisms in reduced folate carrier and gammaglutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics, 2004, 14(11), 733-739
106. van der Straaten, R.J.; Wessels, J.A.; de Vries-Bouwstra, J.K.; Goekoop-Ruiterman, Y.P.; Allaart, C.F.; Bogaartz, J.; Tiller, M.; Huizinga, T.W.; Guchelaar, H.J. Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients. Pharmacogenomics, 2007, 8(2), 141-150
107. Sharma, S.; Das, M.; Kumar, A.; Marwaha, V.; Shankar, S.; Aneja, R.; Grover, R.; Arya, V.; Dhir, V.; Gupta, R.; Kumar, U.; Juyal, R.C.; B, K.T. Interaction of genes from influx-metabolism-efflux pathway and their influence on methotrexate efficacy in rheumatoid arthritis patients among Indians. Pharmacogenet. Genomics, 2008, 18(12), 1041-1049
108. Garcia-Bournissen, F.; Moghrabi, A.; Krajinovic, M. Therapeutic responses in childhood acute lymphoblastic leukemia (ALL) and haplotypes of gamma glutamyl hydrolase (GGH) gene. Leuk. Res., 2007, 31(7), 1023-1025 (Pubitemid 46856715)
109. Cheng, Q.; Cheng, C.; Crews, K.R.; Ribeiro, R.C.; Pui, C.H.; Relling, M.V.; Evans, W.E. Epigenetic regulation of human gammaglutamyl hydrolase activity in acute lymphoblastic leukemia cells. Am. J. Hum. Genet., 2006, 79(2), 264-274 (Pubitemid 44141825)
110. Stranzl, T.; Wolf, J.; Leeb, B.F.; Smolen, J.S.; Pirker, R.; Filipits, M. Expression of folylpolyglutamyl synthetase predicts poor response to methotrexate therapy in patients with rheumatoid arthritis. Clin. Exp. Rheumatol., 2003, 21(1), 27-32. (Pubitemid 36267528)
111. Leil, T.A.; Endo, C.; Adjei, A.A.; Dy, G.K.; Salavaggione, O.E.; Reid, J.R.; Ames, M.M. Identification and characterization of genetic variation in the folylpolyglutamate synthase gene. Cancer Res., 2007, 67(18), 8772-8782 (Pubitemid 47437453)
112. Chango, A.; Emery-Fillon, N.; de Courcy, G.P.; Lambert, D.; Pfister, M.; Rosenblatt, D.S.; Nicolas, J.P. A polymorphism (80G->A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol. Genet. Metab., 2000, 70(4), 310-315
113. Whetstine, J.R.; Gifford, A.J.; Witt, T.; Liu, X.Y.; Flatley, R.M.; Norris, M.; Haber, M.; Taub, J.W.; Ravindranath, Y.; Matherly, L.H. Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers. Clin. Cancer Res., 2001, 7(11), 3416-3422
114. Drozdzik, M.; Rudas, T.; Pawlik, A.; Gornik, W.; Kurzawski, M.; Herczynska, M. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics. J., 2007, 7(6), 404-407 (Pubitemid 350192886)
115. Laverdiere, C.; Chiasson, S.; Costea, I.; Moghrabi, A.; Krajinovic, M. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood, 2002, 100(10), 3832-3834 (Pubitemid 35303961)
116. Imanishi, H.; Okamura, N.; Yagi, M.; Noro, Y.; Moriya, Y.; Nakamura, T.; Hayakawa, A.; Takeshima, Y.; Sakaeda, T.; Matsuo, M.; Okumura, K. Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J. Hum. Genet., 2007, 52(2), 166-171 (Pubitemid 46188292)
117. Yang, R.; Qin, J.; Hoang, B.H.; Healey, J.H.; Gorlick, R. Polymorphisms and methylation of the reduced folate carrier in osteosarcoma. Clin. Orthop. Relat. Res., 2008, 466(9), 2046-2051
118. Chatzikyriakidou, A.; Georgiou, I.; Voulgari, P.V.; Papadopoulos, C.G.; Tzavaras, T.; Drosos, A.A. Transcription regulatory polymorphism -43T>C in the 5′-flanking region of SLC19A1 gene could affect rheumatoid arthritis patient response to methotrexate therapy. Rheumatol. Int., 2007, 27(11), 1057-1061
119. Badagnani, I.; Castro, R.A.; Taylor, T.R.; Brett, C.M.; Huang, C.C.; Stryke, D.; Kawamoto, M.; Johns, S.J.; Ferrin, T.E.; Carlson, E.J.; Burchard, E.G.; Giacomini, K.M. Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J. Pharmacol. Exp. Ther., 2006, 318(2), 521-529
120. Lee, W.; Glaeser, H.; Smith, L.H.; Roberts, R.L.; Moeckel, G.W.; Gervasini, G.; Leake, B.F.; Kim, R.B. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J. Biol. Chem., 2005, 280(10), 9610-9617
121. Abe, T.; Unno, M.; Onogawa, T.; Tokui, T.; Kondo, T.N.; Nakagomi, R.; Adachi, H.; Fujiwara, K.; Okabe, M.; Suzuki, T.; Nunoki, K.; Sato, E.; Kakyo, M.; Nishio, T.; Sugita, J.; Asano, N.; Tanemoto, M.; Seki, M.; Date, F.; Ono, K.; Kondo, Y.; Shiiba, K.; Suzuki, M.; Ohtani, H.; Shimosegawa, T.; Iinuma, K.; Nagura, H.; Ito, S.; Matsuno, S. LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology, 2001, 120(7), 1689-1699
122. van de Steeg, E.; van der Kruijssen, C.M.; Wagenaar, E.; Burggraaff, J.E.; Mesman, E.; Kenworthy, K.E.; Schinkel, A.H. Methotrexate pharmacokinetics in transgenic mice with liverspecific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1). Drug. Metab. Dispos., 2009, 37(2), 277-281
123. Tirona, R.G.; Leake, B.F.; Merino, G.; Kim, R.B. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African- Americans. J. Biol. Chem., 2001, 276(38), 35669-35675 (Pubitemid 37384369)
124. Chen, Z.S.; Lee, K.; Walther, S.; Raftogianis, R.B.; Kuwano, M.; Zeng, H.; Kruh, G.D. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res., 2002, 62(11), 3144-3150
125. Hooijberg, J.H.; Peters, G.J.; Assaraf, Y.G.; Kathmann, I.; Priest, D.G.; Bunni, M.A.; Veerman, A.J.; Scheffer, G.L.; Kaspers, G.J.; Jansen, G. The role of multidrug resistance proteins MRP1, MRP2 and MRP3 in cellular folate homeostasis. Biochem. Pharmacol., 2003, 65(5), 765-771 (Pubitemid 36293693)
126. Kool, M.; van der Linden, M.; de Haas, M.; Scheffer, G.L.; de Vree, J.M.; Smith, A.J.; Jansen, G.; Peters, G.J.; Ponne, N.; Scheper, R.J.; Elferink, R.P.; Baas, F.; Borst, P. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc. Natl. Acad. Sci. USA, 1999, 96(12), 6914-6919 (Pubitemid 29274984)
127. Chen, Z.S.; Robey, R.W.; Belinsky, M.G.; Shchaveleva, I.; Ren, X.Q.; Sugimoto, Y.; Ross, D.D.; Bates, S.E.; Kruh, G.D. Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res., 2003, 63(14), 4048-4054
128. Volk, E.L.; Schneider, E. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res, 2003, 63(17), 5538-5543 (Pubitemid 37139875)
129. Hider, S.L.; Owen, A.; Hartkoorn, R.; Khoo, S.; Back, D.; Silman, A.J.; Bruce, I.N. Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug. Ann. Rheum. Dis., 2006, 65(10), 1390-1393
130. Assaraf, Y.G.; Rothem, L.; Hooijberg, J.H.; Stark, M.; Ifergan, I.; Kathmann, I.; Dijkmans, B.A.; Peters, G.J.; Jansen, G. Loss of multidrug resistance protein 1 expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells. J. Biol. Chem., 2003, 278(9), 6680-6686 (Pubitemid 36800654)
131. Yin, J.Y.; Huang, Q.; Yang, Y.; Zhang, J.T.; Zhong, M.Z.; Zhou, H.H.; Liu, Z.Q. Characterization and analyses of multidrug resistance- associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population. Pharmacogenet. Genomics, 2009, 19(3), 206-216
132. Rau, T.; Erney, B.; Gores, R.; Eschenhagen, T.; Beck, J.; Langer, T. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin. Pharmacol. Ther., 2006, 80(5), 468-476 (Pubitemid 44737489)
133. Hulot, J.S.; Villard, E.; Maguy, A.; Morel, V.; Mir, L.; Tostivint, I.; William-Faltaos, D.; Fernandez, C.; Hatem, S.; Deray, G.; Komajda, M.; Leblond, V.; Lechat, P. A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet. Genomics, 2005, 15(5), 277-285 (Pubitemid 40676548)
134. Mitomo, H.; Kato, R.; Ito, A.; Kasamatsu, S.; Ikegami, Y.; Kii, I.; Kudo, A.; Kobatake, E.; Sumino, Y.; Ishikawa, T. A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport. Biochem. J., 2003, 373(Pt 3), 767-774 (Pubitemid 36981086)
135. Hooijberg, J.H.; Broxterman, H.J.; Kool, M.; Assaraf, Y.G.; Peters, G.J.; Noordhuis, P.; Scheper, R.J.; Borst, P.; Pinedo, H.M.; Jansen, G. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res., 1999, 59(11), 2532-2535 (Pubitemid 29269093)
136. Marzolini, C.; Paus, E.; Buclin, T.; Kim, R.B. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther., 2004, 75(1), 13-33. (Pubitemid 38130115)
137. Pawlik, A.; Wrzesniewska, J.; Fiedorowicz-Fabrycy, I.; Gawronska- Szklarz, B. The MDR1 3435 polymorphism in patients with rheumatoid arthritis. Int. J. Clin. Pharmacol. Ther., 2004, 42(9), 496-503. (Pubitemid 39255621)
138. Drozdzik, M.; Rudas, T.; Pawlik, A.; Kurzawski, M.; Czerny, B.; Gornik, W.; Herczynska, M. The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. Eur. J. Clin. Pharmacol., 2006, 62(11), 933-937 (Pubitemid 44657627)
139. Hirschhorn, J.N.; Lohmueller, K.; Byrne, E.; Hirschhorn, K. A comprehensive review of genetic association studies. Genet. Med., 2002, 4(2), 45-61. (Pubitemid 44698579)
140. Dervieux, T.; Furst, D.; Lein, D.O.; Capps, R.; Smith, K.; Caldwell, J.; Kremer, J. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann. Rheum. Dis., 2005, 64(8), 1180-1185
141. Sorich, M.J.; Pottier, N.; Pei, D.; Yang, W.; Kager, L.; Stocco, G.; Cheng, C.; Panetta, J.C.; Pui, C.H.; Relling, M.V.; Cheok, M.H.; Evans, W.E. In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile. PLoS Med., 2008, 5(4), e83.
142. Ranganathan, P.; Culverhouse, R.; Marsh, S.; Ahluwalia, R.; Shannon, W.D.; Eisen, S.; McLeod, H.L. Single nucleotide polymorphism profiling across the methotrexate pathway in normal subjects and patients with rheumatoid arthritis. Pharmacogenomics, 2004, 5(5), 559-569